High-Throughput Discovery of Inhibitors Targeting Monkeypox Virus H1 Phosphatase
Viruses · 2025
DOI: 10.3390/v17111493 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2025. Verfasst von Chengcheng Tao und 9 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Chongqing Medical University, Chongqing 400016, China. Hauptthemen laut MEDLINE: Antiviral Agents, Monkeypox virus, Enzyme Inhibitors, Phosphoric Monoester Hydrolases. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Program of Chongqing Science and Technology Commission, Science and Technology Research Program of Chongqing Municipal Education Commission.
Abstract (Originalsprache)
Mpox, caused by monkeypox virus (MPXV), remains a Public Health Emergency of International Concern (PHEIC) and poses a serious global health threat. Current therapeutic options for MPXV infection are limited. The orthopoxvirus dual-specificity phosphatase H1 plays critical roles in suppressing interferon signaling, regulating early viral transcription, and modulating viral core protease activity. Suppressing H1 expression markedly reduces the production of infectious viral particles, highlighting it as a promising antiviral target. Here, we developed a high-throughput enzymatic assay using p-nitrophenyl phosphate as a substrate to discover MPXV H1 inhibitors. We demonstrated that both the N-terminal helix α1, which mediates H1 dimerization, and the catalytic residue Cys110 are indispensable for enzymatic activity, validating them as potential “hot spots” for drug design. Screening identified 17 potent inhibitors with nanomolar IC50 values and minimal cytotoxicity. Molecular docking revealed that these inhibitors bind within the active site of MPXV H1, interacting with residues in the P-loop and WPD-loop, thereby restricting substrate access and suppressing activity. This study identifies several potent inhibitors of MPXV H1, establishing a foundation for the development of novel antivirals against MPXV infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmacy, Chongqing Medical University, Chongqing 400016, China.
- Department of Laboratory Medicine, The Affiliated Hospital of Southwest Medical University, Sichuan Province Engineering Technology Research Center of Molecular Diagnosis of Clinical Diseases, Molecular Diagnosis of Cli…
- Center for Novel Target and Therapeutic Intervention, College of Pharmacy, Chongqing Medical University, Chongqing 400016, China.
ORCID-Profile: Mailikezhati Alifu, Junchi Hu
Förderung
- National Natural Science Foundation of China
- Natural Science Program of Chongqing Science and Technology Commission
- Science and Technology Research Program of Chongqing Municipal Education Commission
- CQMU Program for Youth Innovation in Future Medicine
- Undergraduate Research Skills Development Program of College of Pharmacy Chongqing Medical Uni- 400 versity
- Undergraduate Research Skills Development Program of College of Pharmacy Chongqing Medical University
Zitieren
APA
Tao, C., Alifu, M., Huang, H., Luo, Z., Li, Y., Guan, X., Liu, M., Hu, J., Cui, W., & Wang, W. (2025). High-Throughput Discovery of Inhibitors Targeting Monkeypox Virus H1 Phosphatase. Viruses. https://doi.org/10.3390/v17111493
Vancouver
Tao C, Alifu M, Huang H, Luo Z, Li Y, Guan X, et al. High-Throughput Discovery of Inhibitors Targeting Monkeypox Virus H1 Phosphatase. Viruses. 2025. doi:10.3390/v17111493
BibTeX
@article{Tao2025,
author = {Tao, Chengcheng and Alifu, Mailikezhati and Huang, Haojun and Luo, Zhi and Li, Yaxian and Guan, Xuecen and Liu, Mengmeng and Hu, Junchi and Cui, Wen and Wang, Wei},
title = {High-Throughput Discovery of Inhibitors Targeting Monkeypox Virus H1 Phosphatase},
journal = {Viruses},
year = {2025},
doi = {10.3390/v17111493}
}
EUVIMED